Endocrine Abstracts

JOINT922

Objective: The aim of the present study was to evaluate bone mineral density (BMD) and body composition (BC) of patients with transitional growth hormone deficiency (TGHD) treated with once-weekly PEGylated recombinant human growth hormone (Jintrolong) (PEG-rhGH).

Methods: This study was a prospective, multicenter, single arm study with a total of 66 weeks, encompassing a 2-week screening phase, a 12-week dose-adjustment period, and a 52-week treatment phase. The initial dose was 1 mg/w, with subsequent adjustments based on individual IGF-1 levels. BMD and BC were evaluated using dual energy X-ray absorptiometry (DEXA) at baseline, 38 weeks, and 64 weeks.

Results: A total of 31 subjects were included, including 23 males (74.2%) and 8 females (25.8%) with a mean age of 20.46 years. Mean doses in dose stabilization were 3.40 mg/week. The compliance rates nearing 100%. Following a 64-week therapeutic intervention, there was a significant improvement in the IGF-1 Standard Deviation Score (SDS), which increased from a baseline value of -3.07 to -1.38 (P <0.001). Significant improvement in BC was observed, manifesting as percentage of body fat (Fat %) decrease by 2.7% (P <0.001) and LBM increase by 4.54 kilograms (P <0.001), corresponding to a 12% change rate over 64 weeks. Although the lumbar BMD Z-score did not demonstrate statistical significance, there was a numerical increment observed, with an increase of 0.43, elevating the score from -1.54 at baseline to -1.12 post-treatment. In the evaluation of lipid metabolic profiles, a notable decrease was observed exclusively in triglyceride concentrations, which significantly declined from a mean of 1.50 mmol/l to 1.14 mmol/l (P = 0.018). Meanwhile, there was no statistically significant difference in the changes in low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c) and total cholesterol (TC), but there was a tendency for HDL-c to increase.

Conclusion: Our findings indicate that PEG-rhGH therapy is effective in enhancing lean body mass and reducing body fat percentage. These results suggest that PEG-rhGH, with high adherence, may be beneficial in improving BC and BMD in patients with TGHD.